Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
BackgroundHepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) has poor prognosis. Sorafenib/lenvatinib is recommended as the first-line therapy in these patients currently, with unsatisfactory response and survival benefit reported. Radiotherapy (RT) is increasingly util...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020-08-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/article/10.3389/fonc.2020.01589/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|